TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10937676

Group type: EXPERIMENTAL
Intervention: Tamoxifen (higher doses proposed, at least four to eight-fold that of the dose efficacious in an oestrogen-receptor dependent mechanism)
Number of subjects: 0
Study: 8992696

Group type: COMPARATOR
Intervention: Room air (group I)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 80% oxygen (group II)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Comparison of groups
Number of subjects: 70
Study: 1431597

Group type: EXPERIMENTAL
Intervention: Psyllium (15 g/day for 40 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 20
Study: 3883690

Group type: EXPERIMENTAL
Intervention: PGE2 gel (Prostaglandin E2)
Number of subjects: 30
Study: 30368585

Group type: EXPERIMENTAL
Intervention: BNC105P 12 mg/m2 with gemcitabine 1000 mg/m2 and carboplatin AUC4
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BNC105P 16 mg/m2 (maintenance treatment)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BNC105P 800 mg/m2 with gemcitabine and carboplatin AUC4
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BNC105P 1000 mg/m2 with gemcitabine and carboplatin AUC4
Number of subjects: 15
Study: 29359856

Group type: EXPERIMENTAL
Intervention: Flumazenil injection administered i.v. 10 min after transfer to recovery room
Number of subjects: 2

Group type: COMPARATOR
Intervention: No antidote injected (Control group)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Flumazenil injection
Number of subjects: 2
Study: 27169834

Group type: EXPERIMENTAL
Intervention: Inulin-propionate ester
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control inulin
Number of subjects: 20
Study: 24925094

Group type: EXPERIMENTAL
Intervention: True needle acupuncture for ten treatments over eight weeks
Number of subjects: 360

Group type: COMPARATOR
Intervention: Sham acupuncture with non‐insertive (blunt) needles for ten treatments over eight weeks
Number of subjects: 360
Study: 23101480

Group type: EXPERIMENTAL
Intervention: Rituximab in addition to standard treatment with steroid-boli
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard treatment alone (placebo)
Number of subjects: 180
Study: 19701637

Group type: EXPERIMENTAL
Intervention: Tocilizumab, administered in a clinical setting, dosage not specified, duration of treatment not specified.
Number of subjects: 61
Study: 17681004

Group type: EXPERIMENTAL
Intervention: Gaviscon Advance (10 ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New tablet product containing the same active ingredients as Gaviscon Advance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (10 ml water)
Number of subjects: 0
Study: 15452671

Group type: EXPERIMENTAL
Intervention: ACE inhibitors and/or beta-blockers
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control (conventional treatment)
Number of subjects: 167
Study: 12103458

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9682114

Group type: EXPERIMENTAL
Intervention: Heparin-surface-modified (HSM) convex-plano laser-ridge IOL
Number of subjects: 246

Group type: COMPARATOR
Intervention: Conventional unmodified convex-plano lens
Number of subjects: 246
Study: 7598916

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 2113492

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate and human menopausal gonadotropin (hMG); 55 cycles
Number of subjects: 76

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a) and hMG; 38 cycles
Number of subjects: 76
Study: 360842

Group type: EXPERIMENTAL
Intervention: Clotrimazole 1 per cent vaginal cream for 7 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Miconazole nitrate 2 per cent vaginal cream for 14 days
Number of subjects: 65
Study: 31392862

Group type: EXPERIMENTAL
Intervention: Pancreatic Injury with major visceral Vascular Injury (PIVI group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Pancreatic Injury without vascular injury (PI group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: PIVI group
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: PIVI group (AAST grade 1 and 2)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: PIVI group (AAST grade 3, 4 and 5)
Number of subjects: 68
Study: 29178758

Group type: EXPERIMENTAL
Intervention: Mg(OH)2 dentifrice
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NaF (1,450 ppm F) dentifrice
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-fluoride (control) dentifrice
Number of subjects: 18
Study: 26347460

Group type: EXPERIMENTAL
Intervention: One-site phacotrabeculectomy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Two-site phacotrabeculectomy
Number of subjects: 34
Study: 23351825

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 2061

Group type: EXPERIMENTAL
Intervention: Baseline SBP
Number of subjects: 2061

Group type: EXPERIMENTAL
Intervention: Discharge/day 7 SBP
Number of subjects: 2061

Group type: EXPERIMENTAL
Intervention: In-hospital SBP change
Number of subjects: 2061
Study: 21296317

Group type: EXPERIMENTAL
Intervention: Cilotax stent
Number of subjects: 111

Group type: COMPARATOR
Intervention: Taxus Liberte stent
Number of subjects: 111
Study: 19321945

Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 401

Group type: COMPARATOR
Intervention: Sodium ozagrel
Number of subjects: 401
Study: 17296460

Group type: EXPERIMENTAL
Intervention: Imidapril (up to 20 mg/d)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Candesartan (up to 16 mg/d)
Number of subjects: 122
Study: 12575976

Group type: EXPERIMENTAL
Intervention: Exercise training (five-month training program)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-trained control group
Number of subjects: 20
Study: 10526524

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 12
Study: 8544215

Group type: EXPERIMENTAL
Intervention: Oral suspension of antibiotic-resistant Bifidobacterium longum for 30 days, commencing 10-12 days post-irradiation.
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo treatment (control group).
Number of subjects: 5
Study: 1830860

Group type: EXPERIMENTAL
Intervention: Nicotinamide (oral)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 22
Study: 6228933

Group type: EXPERIMENTAL
Intervention: Hydergine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alzheimer's patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Young normals (ages 18-32)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older group (ages 55-69)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elderly group (ages 70-85)
Number of subjects: 0
Study: 31056423

Group type: EXPERIMENTAL
Intervention: Integrative medical group visits intervention
Number of subjects: 338
Study: 26933839

Group type: EXPERIMENTAL
Intervention: Case management intervention (attending five sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Client engagement rating
Number of subjects: 0
Study: 23824632

Group type: EXPERIMENTAL
Intervention: Small-number comparison
Number of subjects: 0

Group type: COMPARATOR
Intervention: Large-number comparison
Number of subjects: 0
Study: 22248500

Group type: EXPERIMENTAL
Intervention: sprint interval exercise
Number of subjects: 10
Study: 19070995

Group type: EXPERIMENTAL
Intervention: Amisulpride (100-400mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Risperidone (1-4mg/day)
Number of subjects: 38
Study: 17311981

Group type: EXPERIMENTAL
Intervention: Probiotics (specific strains not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15213636

Group type: EXPERIMENTAL
Intervention: Gacyclidine 0.02 mg/kg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Gacyclidine 0.005 mg/kg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Gacyclidine 0.001 mg/kg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 11739092

Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 0
Study: 10441239

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 31
Study: 7796359

Group type: EXPERIMENTAL
Intervention: Vecuronium dissolved in normal saline
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vecuronium dissolved in solvent
Number of subjects: 80
Study: 2664089

Group type: EXPERIMENTAL
Intervention: Levodopa (mean dose 444 mg daily)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bromocriptine (mean dose 50 mg daily)
Number of subjects: 28
Study: 918999

Group type: EXPERIMENTAL
Intervention: Chemotherapy prior to radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy with a focal dose of 3000 rd within three weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different chemotherapeutic combinations
Number of subjects: 0
Study: 31292709

Group type: EXPERIMENTAL
Intervention: BCD-055
Number of subjects: 426

Group type: COMPARATOR
Intervention: IFX (innovator infliximab)
Number of subjects: 426
Study: 29156619

Group type: EXPERIMENTAL
Intervention: Calorie-dense and protein-rich early enteral nutrition (1300 Kcal/L and 66.7 g/L protein)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard isocaloric early enteral nutrition (1000 Kcal/L and 38 g/L protein)
Number of subjects: 40
Study: 25907158

Group type: EXPERIMENTAL
Intervention: Idebenone (300 mg three times a day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 23587747

Group type: EXPERIMENTAL
Intervention: Human-computer interaction-based comprehensive cognitive training for 24 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study: 20833659

Group type: EXPERIMENTAL
Intervention: Colonoscopic surveillance in familial colorectal cancer
Number of subjects: 551
Study: 19242030

Group type: EXPERIMENTAL
Intervention: Tepid sponging and antipyretic drug (Paracetamol) (n=73)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Only antipyretic drug (Paracetamol) (n=77)
Number of subjects: 150
Study: 17854249

Group type: EXPERIMENTAL
Intervention: Severity of depression symptoms
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Severity of mania/hypomania symptoms
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Change in depression
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Change in mania/hypomania
Number of subjects: 441
Study: 15082581

Group type: EXPERIMENTAL
Intervention: GFD with additional wheat free oat products (GFD-oats)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard gluten free diet (GFD-std)
Number of subjects: 116
Study: 11717609

Group type: EXPERIMENTAL
Intervention: Systematic study of the eustachian valve in patients suspected of endocarditis
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Culture-guided antibiotics for treatment
Number of subjects: 152

Group type: COMPARATOR
Intervention: Blinded evaluation of eustachian valve findings
Number of subjects: 152
Study: 9204354

Group type: EXPERIMENTAL
Intervention: Iopentol (Imagopaque 300 mg I/ml)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Iopromide (Ultravist 300 mg I/ml)
Number of subjects: 97
Study: 7950109

Group type: EXPERIMENTAL
Intervention: Frown incision (A)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Horizontal arc incision (B)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Limbus-based incision (C)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Trapezoid incision with 2-mm tunnel
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Trapezoid incision with 4-mm tunnel
Number of subjects: 95
Study: 2847843

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 59
Study: 47081

Group type: EXPERIMENTAL
Intervention: Infant feeding-bottle with a valve
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional feeding-bottles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard teat under valve conditions
Number of subjects: 0
Study: 30839402

Group type: EXPERIMENTAL
Intervention: Huperzine-A treatment for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 50
Study: 29236711

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 61

Group type: COMPARATOR
Intervention: DCE‐MRI and RAMRIS
Number of subjects: 61

Group type: COMPARATOR
Intervention: RAMRIS and CARLOS
Number of subjects: 61
Study: 26179113

Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (3 g/day) with low-calorie diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (3 g/day) with low-calorie diet
Number of subjects: 50
Study: 23388213

Group type: EXPERIMENTAL
Intervention: Active cardiac resynchronization therapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: Inactive cardiac resynchronization therapy
Number of subjects: 85
Study: 21973230

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19339233

Group type: EXPERIMENTAL
Intervention: 30 mg meloxicam (formulation 1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg meloxicam (formulation 2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 12
Study: 22795204

Group type: EXPERIMENTAL
Intervention: ABT-089 40 mg once daily
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: ABT-089 80 mg once daily
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 15993398

Group type: EXPERIMENTAL
Intervention: Actor grasping the object inside the short frame
Number of subjects: 100

Group type: COMPARATOR
Intervention: Actor grasping the object inside the long frame
Number of subjects: 100
Study: 12447010

Group type: EXPERIMENTAL
Intervention: Didanosine EC (400 mg once daily), Stavudine (40 mg twice daily), Nelfinavir (750 mg three times daily)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Zidovudine (300 mg twice daily) plus Lamivudine (150 mg twice daily) and Nelfinavir (750 mg three times daily)
Number of subjects: 511
Study: 9804035

Group type: EXPERIMENTAL
Intervention: Recovered depressed subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control groups
Number of subjects: 0
Study: 7638372

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 50 micrograms twice daily
Number of subjects: 225

Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) 20 mg four times daily
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 225
Study: 2797637

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (50-100 micrograms every hour)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Meperidine (25-50 mg every 2-3 hours)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 105

Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 105
Study: 355954

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study: 11673575

Group type: COMPARATOR
Intervention: rizatriptan 10 mg
Number of subjects: 4064
Study: 31499564

Group type: EXPERIMENTAL
Intervention: Light load (LIT) - 25-30 repetitions maximum (RM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Moderate load (MOD) - 8-12 repetitions maximum (RM)
Number of subjects: 12
Study: 30253264

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a‐tDCS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham/placebo stimulation
Number of subjects: 36
Study: 28139613

Group type: EXPERIMENTAL
Intervention: BCD-063 (glatiramer acetate)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Copaxone-Teva (glatiramer acetate)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 23983082

Group type: EXPERIMENTAL
Intervention: NURTURE intervention (weekly for 16 sessions, 1.5 hours each)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: NURTURE intervention
Number of subjects: 13
Study: 22380529

Group type: EXPERIMENTAL
Intervention: LAR 30 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: LAR 10 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: LAR 30 mg, LAR 10 mg, Saline (Control)
Number of subjects: 39
Study: 20007995

Group type: EXPERIMENTAL
Intervention: Bespoke external support placement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (unoperated Marfan patients)
Number of subjects: 10
Study: 18377782

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish consumption (oily fish such as salmon)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced tissue/blood levels of LC n-3 FAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LC n-3 FA supplementation in cardiac surgery patients
Number of subjects: 0
Study: 15023167

Group type: EXPERIMENTAL
Intervention: Tenatoprazole 40 mg (T40)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tenatoprazole 20 mg (T20)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg (E40)
Number of subjects: 18
Study: 11792778

Group type: EXPERIMENTAL
Intervention: Bone-vacuum technique
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard cementing technique (Control)
Number of subjects: 130
Study: 9583368

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented TPN (0.22 g glutamine x kg(‐1) x d(‐1) as glycyl‐glutamine)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional TPN
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented TPN
Number of subjects: 14
Study: 7658051

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 150
Study: 2651861

Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study: 345709

Group type: EXPERIMENTAL
Intervention: Collagen film implantation
Number of subjects: 50
Study: 30398542

Group type: EXPERIMENTAL
Intervention: Intensive patient education (2 x 1-hour sessions providing information on pain and biopsychosocial contributors plus self-management techniques)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo patient education (active listening without information or advice)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Intensive patient education
Number of subjects: 202
Study: 28548301

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure withdrawal
Number of subjects: 77
Study: 25837215

Group type: EXPERIMENTAL
Intervention: Low PRAL group
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Pro:K
Number of subjects: 547
Study: 23256605

Group type: EXPERIMENTAL
Intervention: Freestyle Navigator (FSN)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Dexcom SEVEN PLUS (DSP)
Number of subjects: 52
Study: 21622587

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg q.d.
Number of subjects: 1598

Group type: COMPARATOR
Intervention: Tiotropium 18 μg q.d.
Number of subjects: 1598
Study: 18655566

Group type: EXPERIMENTAL
Intervention: E-leng Capsule (ELC) administered before and after operation for 3 months starting from the 7th day post-operation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Danazol administered from the 7th day post-operation for 3 months (Control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: E-leng Capsule (ELC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Danazol (Control group)
Number of subjects: 60
Study: 16959188

Group type: EXPERIMENTAL
Intervention: 1% lidocaine 4 mL with 20 microg epinephrine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1% lidocaine 4 mL with 40 microg epinephrine
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1% lidocaine 4 mL with 0 microg epinephrine
Number of subjects: 90
Study: 12792424

Group type: EXPERIMENTAL
Intervention: Mock report with comprehensive content
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mock report with less comprehensive content
Number of subjects: 0
Study: 10690160

Group type: COMPARATOR
Intervention: saccharin (control, 23 kJ)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 40 g sucrose (859 kJ)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 40 g maize oil (1569 kJ)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 20 g sucrose, 20 g maize oil (1213 kJ)
Number of subjects: 80
Study: 8623811

Group type: EXPERIMENTAL
Intervention: P6 acupressure
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo (acupressure bands inappropriately placed)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control
Number of subjects: 161
Study: 1773870

Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 in solid gel (Cerviprost)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.5 mg PGE2 in liquid cellulose-gel
Number of subjects: 80
Study: 6115001

Group type: EXPERIMENTAL
Intervention: TPN
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (glucose-electrolyte)
Number of subjects: 21
Study: 31090511

Group type: EXPERIMENTAL
Intervention: 100 mg SHIP1 activator
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: 200 mg SHIP1 activator
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 28183441

Group type: EXPERIMENTAL
Intervention: SITLegs (repeated sprints on a cycle ergometer)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SITArms (repeated sprints on an arm-crank ergometer)
Number of subjects: 12

Group type: COMPARATOR
Intervention: END (50-min continuous cycling at 65% V̇O2max)
Number of subjects: 12
Study: 25125635

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 22661410

Group type: EXPERIMENTAL
Intervention: TMS over the left pre-SMA (5 pulses, 10 Hz)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vertex stimulation (control condition)
Number of subjects: 18